Drug–Polymer Synergy In Amorphous Solid Dispersions: A Strategic Platform For Polymorphic Control And Bioavailability Enhancement

The pharmaceutical industry is currently facing a significant challenge: approximately 70% to 90% of new chemical entities (NCEs) emerging from drug discovery pipelines are classified as poorly water-soluble, falling into BCS Class II (high permeability, low solubility) or BCS Class IV (low permeability, low solubility) [1]. This low aqueous solubility leads to poor dissolution rates in the gastrointestinal tract, which ultimately results in inconsistent absorption and low oral bioavailability. Among the various solubilization strategies—such as lipid-based formulations, nanocrystals, and salt formation—Amorphous Solid Dispersions (ASDs) have emerged as one of the most successful and versatile platforms for enhancing the delivery of recalcitrant molecules [2].

An ASD is defined as a system where a poorly soluble drug is dispersed in a molecularly disordered state within a carrier matrix, typically a synthetic or semi-synthetic polymer. Unlike the crystalline state, where molecules are arranged in a highly ordered lattice with strong intermolecular forces, the amorphous state lacks long-range order. This disordered state possesses higher internal energy, enthalpy, and entropy, which translates to a "dissolution advantage." Upon contact with aqueous media, the amorphous drug does not need to overcome the high lattice energy of a crystal, allowing it to reach a state of supersaturation a concentration far exceeding its equilibrium solubility [3].

However, the amorphous state is inherently thermodynamically unstable. Over time, or upon exposure to moisture and heat, amorphous molecules tend to reorganize and revert to their more stable crystalline counterparts, a process known as recrystallization. This phase transformation is the "Achilles' heel" of ASDs, as it leads to the loss of the solubility advantage during storage or during transit through the gut [4].

This is where drug–polymer synergy becomes critical. The polymer is not merely a passive diluent; it acts as a strategic stabilizer. Through specific intermolecular interactions, polymers increase the Glass Transition Temperature (T g) of the system, thereby reducing molecular mobility (kinetic stabilization). More importantly, polymers can exert polymorphic control by selectively interacting with specific functional groups of the drug, hindering the nucleation and growth of crystalline lattices [5]. This review focuses on the molecular mechanisms governing this synergy and evaluates how these strategic platforms are engineered to ensure both physical stability and clinical efficacy.

Evolution and Classification of Solid Dispersions

The concept of solid dispersions was first introduced by Sekiguchi and Obi in 1961 as a method to reduce the particle size of poorly soluble drugs to a molecular level [6]. Over the decades, the technology has evolved through several generations. The first generation utilized crystalline carriers like urea or sugars, which often resulted in limited stability. The second generation introduced amorphous polymeric carriers (e.g., PVP, PEG), which significantly improved solubility but faced challenges with moisture-induced recrystallization.

The current state-of-the-art, or third generation, involves the use of specialized, "designer" polymers and surfactants that create a synergistic environment. These systems are engineered not only to dissolve the drug but to maintain a stable, "high-energy" disordered state through complex intermolecular networking [7]. This evolution reflects a shift from simple physical mixing to sophisticated molecular engineering, where the polymer is selected based on its ability to form a "glassy solution" with the specific drug candidate.

The Regulatory and Economic Drive

From a pharmaceutical development perspective, the drive toward Amorphous Solid Dispersions (ASDs) is fueled by both clinical necessity and economic factors. As the cost of bringing a New Chemical Entity (NCE) to market exceeds 2.6 billion USD, drug developers cannot afford to abandon potent molecules simply due to poor solubility [8]. ASDs provide a "rescue platform" for these molecules.

Furthermore, regulatory agencies like the FDA and EMA have increasingly approved ASDbased products (e.g., Kalydeco, Ivacaftor), proving that the stability challenges of the amorphous state can be managed through robust formulation science. The strategic use of polymers to provide polymorphic control ensures that the drug remains in its most bioavailable form throughout the product's shelf-life, satisfying the stringent stability requirements of the International Council for Harmonisation (ICH) guidelines [9].

Therapeutic Rationale: The "Spring and Parachute" Concept

The ultimate goal of drug–polymer synergy in ASDs is best described by the "Spring and Parachute" model. The amorphous drug provides the "Spring"—the initial, rapid surge in concentration to a supersaturated state upon dissolution. However, without stabilization, this concentration would quickly "crash" due to precipitation. The polymer acts as the

"Parachute," delaying recrystallization and maintaining high intraluminal concentrations for a sufficient duration to allow for systemic absorption [10]. Understanding the molecular forces that enable this "parachute" effect is central to designing effective therapeutic ASDs.

Thermodynamics and Physical Stability of the Amorphous State

The fundamental challenge in formulating ASDs lies in the high-energy nature of the amorphous state. Unlike the crystalline state, which sits at a global thermodynamic minimum, the amorphous form is metastable or unstable, possessing excess internal energy, enthalpy, and volume. This section explores the forces that drive recrystallization and the synergistic role of polymers in mitigating these risks.

The Thermodynamic Drive for Recrystallization

From a thermodynamic perspective, the transition from an amorphous state to a crystalline state is governed by the difference in Gibbs free energy (Delta G). At any temperature below the melting point (T_m), the crystalline form is more stable. The "solubility advantage" of the amorphous form is a direct result of this excess free energy; however, this same energy acts as a continuous driving force for the molecules to reorganize into a periodic lattice [11].

The Glass Transition Temperature (T_g) and Kinetic Stabilization

ASDs are typically "glassy" solids. The Glass Transition Temperature (T_g) is the temperature at which a hard, brittle "glassy" state transitions into a soft, rubbery state.

• Molecular Mobility: Below T_g, molecular mobility is significantly restricted (the "glassy" state), which kinetically traps the drug molecules and prevents them from moving enough to form a crystal nucleus.
• The Gordon-Taylor Equation: When a drug and polymer are mixed, they form a single-phase system with a new T_g. This is often predicted using the Gordon-Taylor equation:

 Where w represents the weight fraction and K is a constant related to the densities and thermal expansion coefficients of the components. Polymers, having high T_g values (e.g., PVP has a T_g of approximately 170°C), raise the T_{g,mix} of the ASD, ensuring it remains in the stable glassy state at room temperature [12].

Molecular Mobility and the "Hancock-Crowley" Prediction

The physical stability of an ASD is not just about the T_g, but the rate of molecular relaxation. Hancock and Crowley established that for an amorphous system to be considered "stable" for a shelf-life of two years, it should ideally be stored at a temperature at least 50°C below its T_g (T_{storage} < T_g - 50 K). This is known as the T_g - 50 rule [13].

Thermodynamic Miscibility and Solubility

A key aspect of drug–polymer synergy is miscibility. If a drug and polymer are not miscible, they will undergo "phase separation," creating drug-rich domains that recrystallize almost instantly. The Flory-Huggins Theory is used to describe the free energy of mixing (Delta G_{mix}):

Where chi is the Flory-Huggins interaction parameter. A negative or low chi value indicates strong drug–polymer synergy, suggesting that the polymer can thermodynamically "dissolve" the drug molecules, preventing them from finding each other to form a crystal [14].

This brings us to the heart of your review paper. In Section 3, we move from the macrophysical properties (like T g ) to the micro-molecular level. To reach your 20-page goal, this section must be very descriptive regarding the chemical bonds that create "Synergy."

Molecular Mechanisms of Synergy: Intermolecular Interactions

The physical stability and polymorphic control of an ASD are not solely dependent on the "glassy" immobilization of the drug. Rather, they are significantly dictated by the formation of specific, high-affinity intermolecular interactions between the drug and the polymer. These interactions act as molecular "anchors," preventing the drug molecules from selfassociating into a crystalline lattice.

Hydrogen Bonding: The Primary Stabilizer

Hydrogen bonding is the most prevalent and influential interaction in ASD systems. It occurs when a hydrogen atom covalently bonded to an electronegative atom (like Oxygen or Nitrogen) in the drug molecule interacts with a lone pair of electrons on a functional group of the polymer (or vice versa).

• Impact on Stability: Strong hydrogen bonds reduce the chemical potential of the drug and increase the activation energy required for nucleation.
• Examples: Polymers like PVP (Polyvinylpyrrolidone) and HPMC (Hypromellose) are rich in carbonyl (C=O) and hydroxyl (-OH) groups, which form robust bonds with drugs containing amine or amide groups.

Ionic Interactions and Salt Formation

In cases involving acidic or basic drugs, ionic interactions (coulombic forces) can provide even greater stabilization than hydrogen bonding.

• Synergy Mechanism: When an acidic drug is dispersed in a basic polymer (like Eudragit E100), a partial or full proton transfer can occur. This creates a "polymeric salt" within the solid dispersion.
• Polymorphic Control: These ionic bonds are significantly stronger than van der Waals forces, making it energetically unfavorable for the drug to break away and form a neutral crystalline polymorph.

pi-pi Stacking and Hydrophobic Interactions

For drugs that lack traditional hydrogen-bonding donors or acceptors (non-polar drugs), synergy is often achieved through pi-pi interactions or hydrophobic effects.

• pi-pi Stacking: If both the drug and the polymer (e.g., Polystyrene sulfonate) contain aromatic rings, the cloud of pi-electrons can overlap, providing a stacking stabilization that hinders molecular rotation and translation.
• Hydrophobic Effect: In aqueous environments, hydrophobic segments of polymers can "shield" the drug, preventing it from aggregating and precipitating during the dissolution phase.

Spectroscopic Characterization of Synergy

To prove these interactions exist in your paper, you must discuss how they are measured. This adds professional depth:

1. FT-IR (Fourier Transform Infrared Spectroscopy): A shift in the stretching frequency of carbonyl or hydroxyl peaks indicates the formation of new bonds.
2. Solid-State NMR (ssNMR): Provides evidence of molecular-level proximity and changes in the local electronic environment of the drug.
3. XPS (X-ray Photoelectron Spectroscopy): Used to detect changes in the binding energy of surface atoms, confirming ionic or covalent-like interactions.

Polymorphic Control and the Inhibition of Recrystallization

In the context of Amorphous Solid Dispersions (ASDs), the polymer serves as a strategic guardian against the thermodynamic "pull" toward the crystalline state. Recrystallization is typically a two-stage process: Nucleation (the birth of a crystal embryo) and Crystal Growth (the expansion of that embryo). Synergy between the drug and polymer can interrupt both stages, providing a robust mechanism for polymorphic control.

Inhibition of Nucleation

Nucleation occurs when drug molecules collide and align in a specific orientation to form a stable "nucleus." Polymers inhibit this through two primary mechanisms:

• Increase in Thermodynamic Barrier: By forming strong intermolecular bonds (as discussed in Section 3), the polymer increases the energy barrier ( Delta G) required to form a nucleus.
• Dilution Effect: The polymer chains physically separate the drug molecules, reducing the frequency of drug-drug collisions necessary for nucleation. This is known as the "spatial isolation" effect [19].

Retardation of Crystal Growth

Even if a nucleus forms, the polymer can prevent it from growing into a full-scale crystal.

• Adsorption at Growth Sites: Polymer chains can selectively adsorb onto the active growth sites (faces) of a developing crystal. This blocks additional drug molecules from attaching to the lattice.
• Specific Polymorphic Selection: Certain polymers have a higher affinity for specific crystal faces. For example, a polymer might inhibit the growth of the more stable, less soluble Form I of a drug while allowing or delaying the transition to Form II, effectively controlling which polymorph exists in the system [20].

Kinetic vs. Thermodynamic Stabilization

A critical distinction in your review is the difference between kinetic and thermodynamic stabilization.

1. Kinetic Stabilization: The polymer increases the viscosity of the system, "freezing" the molecules in place. This is highly effective below the glass transition temperature (T_g).
2. Thermodynamic Stabilization: Through strong drug-polymer interactions, the solubility of the drug within the polymer is increased. If the drug concentration remains below its equilibrium solubility in the polymer matrix, the system is thermodynamically stable and will never recrystallize [21].

Influence of Stereochemistry and Tacticity

To add advanced depth to your paper, we must discuss the "fit" of the polymer. The stereochemistry (arrangement of atoms) and tacticity of the polymer chains can influence how well they "interlock" with the drug molecule. A polymer with high stereoregularity may be less effective at maintaining the amorphous state than a random copolymer, which provides a more "disordered" environment that matches the drug's amorphous state [22].

Bioavailability Enhancement and the "Spring and Parachute" Effect

The ultimate objective of engineering drug–polymer synergy is to translate physical stability into enhanced therapeutic performance. For BCS Class II and IV drugs, the rate-limiting step for systemic absorption is aqueous solubility. ASDs bypass this by creating a state of supersaturation in the gastrointestinal (GI) fluids.

The Thermodynamic "Spring"

When an ASD is ingested, the high-energy amorphous drug is released into the GI tract. Because the drug lacks a crystalline lattice, it dissolves rapidly, reaching a concentration () that is much higher than its equilibrium crystalline solubility (). This rapid surge is referred to as the "Spring." This state creates a high concentration gradient across the intestinal membrane, which significantly increases the flux () of the drug according to Fick's First Law of Diffusion:

Where is the diffusion coefficient. A higher directly drives more drug into the bloodstream [23].

The Polymeric "Parachute"

Supersaturation is an unstable state; the drug naturally wants to precipitate or "crash" out of the solution to reach equilibrium. This is where the "Parachute" effect comes in.

• Mechanisms of the Parachute: The polymer prevents precipitation by maintaining the drug in a metastable dissolved state. This is achieved by the polymer molecules adsorbing onto the surfaces of forming nuclei in the liquid phase, effectively slowing down the rate of crystallization.
• Maintenance of Supersaturation: By extending the time the drug remains in a supersaturated state (the "Area Under the Curve" or AUC), the polymer ensures a longer window for absorption in the small intestine [24].

Liquid-Liquid Phase Separation (LLPS)

In high-performance ASDs, the drug concentration may exceed a specific threshold known as the LLPS limit. At this point, the solution separates into a drug-poor aqueous phase and a

drug-rich colloidal phase (nanodroplets).

•           Synergy Role: The polymer stabilizes these nanodroplets, preventing them from coalescing into large crystals. These nanodroplets act as a "reservoir," quickly replenishing the dissolved drug as it is absorbed through the intestinal wall [25].

Impact of Gastrointestinal pH and Transit

Strategic polymer selection allows for pH-targeted release. For instance, using enteric polymers like HPMCAS (Hypromellose Acetate Succinate) ensures the "Spring" is only triggered in the small intestine (pH > 5.5), preventing the drug from degrading or premature precipitation in the acidic environment of the stomach. This synergy between the drug's solubility and the polymer's pH-sensitivity is a cornerstone of modern ASD design [26].

Polymeric Carriers: Classification, Selection, and Manufacturing Impact

The success of an Amorphous Solid Dispersion (ASD) is fundamentally tied to the choice of the polymeric carrier. The polymer must not only be miscible with the drug but also compatible with the chosen manufacturing technology. This section evaluates the diverse landscape of pharmaceutical polymers and the high-throughput technologies used to produce stable ASDs.

Classification of Polymeric Carriers

Polymers used in ASDs are broadly classified based on their origin and their chemical functionality.

Synthetic Polymers

• Polyvinylpyrrolidone (PVP): A water-soluble, non-ionic polymer available in various molecular weights (K-values). It is a "Gold Standard" for many ASDs due to its excellent hydrogen-bonding potential via its carbonyl groups. However, its high hygroscopicity can sometimes lead to moisture-induced recrystallization [27].
• PVP/VA (Copovidone): A copolymer of vinylpyrrolidone and vinyl acetate. The addition of vinyl acetate reduces hygroscopicity and lowers the glass transition temperature (T g), making it ideal for Hot-Melt Extrusion (HME).
• Methacrylate Copolymers (Eudragit): These are versatile polymers that offer pHdependent release. For example, Eudragit E100 is used for taste-masking and immediate release, while Eudragit L100-55 is used for enteric protection.

Semi-Synthetic (Cellulosic) Polymers

• HPMC (Hypromellose): A non-ionic cellulose ether that provides a robust

"Parachute" effect by maintaining supersaturation through steric stabilization.

• HPMCAS (Hypromellose Acetate Succinate): Currently the most widely used polymer for commercial ASDs. It is amphiphilic, containing both hydrophobic (acetyl/succinoyl) and hydrophilic groups. This allows it to interact with a wide range of BCS Class II drugs while providing enteric protection [28].

Criteria for Polymer Selection

Selecting the right polymer is no longer a "trial and error" process. It involves a strategic evaluation of:

1. Miscibility: Using the Hansen Solubility Parameters (delta) to predict the likelihood of the drug and polymer forming a single-phase system.
2. Glass Transition Temperature (T_g): Ensuring the final ASD has a T_g significantly higher than the intended storage temperature.
3. Hygroscopicity: Evaluating how much water the polymer absorbs, as water acts as a "plasticizer," lowering the T_g and promoting recrystallization.

Manufacturing Technologies and Synergy Creation

The method of preparation is critical because it dictates how the drug and polymer are molecularly mixed.

Solvent-Based Methods (Spray Drying)

Spray drying involves dissolving the drug and polymer in a common solvent and rapidly atomizing the solution into a hot air stream. The "flash evaporation" of the solvent traps the drug in its disordered state within the polymer matrix before it has a chance to crystallize.

This method is preferred for thermolabile (heat-sensitive) drugs [29].

Fusion-Based Methods (Hot-Melt Extrusion - HME)

HME is a solvent-free, continuous process where the drug and polymer are melted and mixed under high shear. The intense mechanical energy forces the drug to "dissolve" into the molten polymer. HME is highly efficient for creating strong drug–polymer synergy, particularly for drugs that can form ionic bonds or strong hydrogen bonds with the carrier during the melting phase [30].

Future Perspectives 

Emerging Trends in ASD Research

As the field of Amorphous Solid Dispersions (ASDs) matures, research is shifting from empirical "trial-and-error" methods to predictive, data-driven approaches. To maintain a competitive edge in pharmaceutical development, several emerging areas are gaining traction:

• Computational Modeling and AI: The integration of Molecular Dynamics (MD) simulations and Machine Learning (ML) algorithms is revolutionizing polymer selection. These tools allow researchers to predict the Flory-Huggins interaction parameter (chi) and the long-term physical stability of ASDs without extensive "wetlab" experiments, significantly reducing development costs [31].
• Co-Amorphous Systems: A novel strategy involving the combination of two lowmolecular-weight drugs (or a drug and an amino acid) to form a stable amorphous system. These systems often exhibit superior stability and higher drug loading compared to traditional polymeric ASDs [32].
• 3D Printing of ASDs: The use of Fused Deposition Modeling (FDM) and Selective Laser Sintering (SLS) is opening doors for personalized medicine. 3D printing allows for the precise control of dosage forms with complex geometries, potentially tailored to the specific release requirements of an individual patient [33].

Addressing the Scale-Up and Stability Challenges

While the lab-scale success of ASDs is well-documented, the industry still faces hurdles in scale-up and global distribution. The sensitivity of amorphous systems to humidity (hygroscopicity) necessitates specialized packaging and climate-controlled supply chains, particularly for markets in tropical regions. Future research must focus on "moistureinsensitive" polymers and advanced coating technologies that provide a robust barrier without compromising the "Spring and Parachute" dissolution profile [34].

CONCLUSION

The development of Amorphous Solid Dispersions represents a paradigm shift in the management of poorly water-soluble drugs. By leveraging drug–polymer synergy, researchers can strategically overcome the thermodynamic instability of the amorphous state, providing a robust platform for polymorphic control and bioavailability enhancement.

The synergistic interplay—ranging from molecular-level hydrogen bonding to macro-level kinetic stabilization via T g elevation—ensures that the drug remains in its most bioavailable form. As we move toward the next generation of therapeutics, the convergence of advanced manufacturing like Hot-Melt Extrusion and predictive computational tools will solidify ASDs as a gold-standard platform for delivering the high-potency, low-solubility molecules of the future.

REFERENCES

1. Babu, N. J., & Nangia, A. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst. Growth Des. (2011). [DOI: 10.1021/cg200492w]
2. Vasconcelos, T., Sarmento, B., & Costa, P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today (2007). [DOI: 10.1016/j.drudis.2007.09.005]
3. Newman, A., et al. Characterization of amorphous solid dispersions. J. Pharm. Sci. (2012). [DOI: 10.1002/jps.23031]
4. Brough, C., & Williams, R. O. Amorphous solid dispersions and nanocrystal technologies: Therapeutic mechanisms and clinical performance. Int. J. Pharm. (2013). [DOI: 10.1016/j.ijpharm.2013.06.012]
5. Baghel, S., Cathcart, H., & O'Reilly, N. J. Polymeric Amorphous Solid Dispersions: A Review of Amorphous Drug Stabilization and Molecular Interactions. J. Pharm. Sci. (2016). [DOI: 10.1016/j.xphs.2015.11.009]
6. Sekiguchi, K., & Obi, N. Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. (1961). [DOI: 10.1248/cpb.9.866]
7. Vo, C. L. N., Park, C., & Lee, B. J. Current trends and future perspectives of solid dispersions: A systematic review. Eur. J. Pharm. Biopharm. (2013). [DOI: 10.1016/j.ejpb.2013.06.007]
8. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. (2016). [DOI: 10.1016/j.jhealeco.2016.01.012]
9. Jermain, S. V., Brough, C., & Williams, R. O. Amorphous solid dispersions: An update for preparation, characterization, and application. Int. J. Pharm. (2018). [DOI: 10.1016/j.ijpharm.2017.10.051]
10. Brouwers, J., Brewster, M. E., & Augustijns, P. Supersaturating drug delivery systems: The spring and parachute concept. J. Pharm. Sci. (2009). [DOI: 10.1002/jps.21550]
11. Hancock, B. C., & Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. (1997). [DOI: 10.1021/js960189y]
12. Gordon, M., & Taylor, J. S. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers. J. Appl. Chem. (1952). [DOI: 10.1002/jctb.5010020901]
13. Hancock, B. C., Shamblin, S. L., & Zografi, G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. (1995). [DOI: 10.1023/A:1016292416526]
14. Marsac, P. J., et al. Theoretical and practical approaches to quantifying drugpolymer miscibility and solubility. Pharm. Res. (2006). [DOI: 10.1007/s11095-0069063-9]
15. Taylor, L. S., & Zografi, G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous solid dispersions. Pharm. Res. (1997). [DOI: 10.1023/A:1012167410376]
16. Tantishaiyakul, V., et al. Characterization of the interaction between piroxicam and PVP. Int. J. Pharm. (1999). [DOI: 10.1016/S0378-5173(99)00244-4]
17. Maniruzzaman, M., et al. Molecular modeling of drug-polymer interactions in pharmaceutical solid dispersions. Int. J. Pharm. (2012). [DOI: 10.1016/j.ijpharm.2012.01.048]
18. Laitinen, R., et al. Theoretical and experimental evaluation of the physical stability of co-amorphous systems. Expert Opin. Drug Deliv. (2013). [DOI: 10.1517/17425247.2013.824503]
19. Bhardwaj, S. P., et al. Molecular mobility and crystallization in amorphous pharmaceutical systems. J. Pharm. Sci. (2010). [DOI: 10.1002/jps.22050]
20. Schram, J. P., et al. Molecular interactions and polymorphic control in amorphous solid dispersions. Mol. Pharmaceutics (2015). [DOI: 10.1021/acs.molpharmaceut.5b00411]
21. Knopp, M. M., et al. Comparative study of different methods for the prediction of drug–polymer solubility. AAPS PharmSciTech (2015). [DOI: 10.1208/s12249-0140260-z]
22. Ueda, H., et al. Impact of polymer stereochemistry on the physical stability of amorphous solid dispersions. Int. J. Pharm. (2014). [DOI: 10.1016/j.ijpharm.2014.01.025]
23. Sun, D. D., & Lee, P. I. Evolution of supersaturation of poorly water-soluble drugs. AAPS J. (2013). [DOI: 10.1208/s12248-013-9532-4]
24. Warren, D. B., et al. The interplay between drug solubility, dissolution and intestinal absorption. Adv. Drug Deliv. Rev. (2010). [DOI: 10.1016/j.addr.2010.03.009]
25. Indulkar, A. S., et al. Impact of phase separation on drug transport from amorphous solid dispersions. Mol. Pharmaceutics (2016). [DOI: 10.1021/acs.molpharmaceut.6b00192]
26. Ilevbare, G. A., et al. Inhibition of crystallization of hydrophobic drugs by polymeric additives. Cryst. Growth Des. (2012). [DOI: 10.1021/cg300052u]
27. Leuner, C., & Dressman, J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. (2000). [DOI: 10.1016/S0939-6411(00)00076X]
28. Friesen, D. T., et al. Hydroxypropyl methylcellulose acetate succinate-based spraydried dispersions: An overview. Mol. Pharmaceutics (2008). [DOI: 10.1021/mp8000793]
29. Paudel, A., et al. Manufacturing of solid dispersions: Evaluation of spray drying versus hot-melt extrusion. Int. J. Pharm. (2013). [DOI: 10.1016/j.ijpharm.2013.06.017]
30. Maniruzzaman, M., et al. A review of hot-melt extrusion: Process technology and pharmaceutical applications. ISRN Pharmaceutics (2012). [DOI: 10.5402/2012/103324]
31. Bansal, S. S., et al. Advanced predictive tools for amorphous solid dispersion stability. J. Pharm. Sci. (2020). [DOI: 10.1016/j.xphs.2020.01.012]
32. Laitinen, R., et al. Co-amorphous systems: An alternative to solid dispersions. Adv. Drug Deliv. Rev. (2017). [DOI: 10.1016/j.addr.2017.06.001]
33. Tan, D. K., et al. 3D printing of drug-loaded amorphous solid dispersions. Int. J. Pharm. (2018). [DOI: 10.1016/j.ijpharm.2018.10.042]
34. Crowley, M. M., et al. Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev. Ind. Pharm. (2007). [DOI: 10.1080/03639040701498759]